# Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors

> **NCT06993844** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ensem Therapeutics** · enrollment: 233 (estimated)

## Conditions studied

- Advanced Solid Tumors
- Advanced Breast Cancer

## Interventions

- **DRUG:** ETX-636 dose escalation
- **DRUG:** ETX-636 dose escalation in combination with fulvestrant
- **DRUG:** ETX-636 dose expansion in combination with fulvestrant

## Key facts

- **NCT ID:** NCT06993844
- **Lead sponsor:** Ensem Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-10
- **Primary completion:** 2027-06-30
- **Final completion:** 2027-12-30
- **Target enrollment:** 233 (ESTIMATED)
- **Last updated:** 2026-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06993844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06993844, "Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT06993844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*